Stock Comparison

PFE vs TMDX

Pfizer Inc vs Transmedics Group Inc

The Verdict

TMDX takes this one.

PFE

Pfizer Inc

4.0

out of 10

Proceed with Caution

Winner

TMDX

Transmedics Group Inc

6.8

out of 10

Solid Pick

Head-to-Head

$146.4B

Market Cap

$2.5B

19.5

P/E Ratio

14.8

11.8%

Profit Margin

27.0%

8.4%

Return on Equity

41.9%

0.7

Debt-to-Equity

1.1

Moderate

Overall Risk

Aggressive

4.0

DVR Score

6.8

The Deep Dive

PFE4.0/10

Pfizer Inc. remains a mature, large-cap pharmaceutical company with limited potential for the requested 10x growth within 3-5 years, which would require a market cap exceeding $1.4 trillion. While Q1 2026 results showed revenue of $14.45B and adjusted EPS of $0.75, both beating estimates, YoY revenue growth was modest at +5.4% and adjusted EPS declined -18%. Strategic legal wins for VYNDAQEL and C...

Full PFE Analysis

TMDX6.8/10

Transmedics (TMDX) maintains a compelling long-term thesis driven by its market-leading Organ Care System (OCS) and strategic expansion into integrated organ logistics (NOCS). The Q1 2026 results confirmed robust +21.2% YoY revenue growth, and FY2026 guidance was reiterated, reflecting continued management confidence in the NOCS rollout. However, the Q1 EPS of $0.30 significantly missed consensus ...

Full TMDX Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.